Prophase Labs Stock Today
| PRPH Stock | USD 6.27 1.08 14.69% |
Performance8 of 100
| Odds Of DistressLess than 13
|
ProPhase Labs is trading at 6.27 as of the 18th of April 2024. This is a -14.69% down since the beginning of the trading day. The stock's open price was 7.35. ProPhase Labs has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for ProPhase Labs are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of April 2023 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of January 1997 | Category Healthcare | Classification Health Care |
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. The company has 18.05 M outstanding shares of which 257.32 K shares are at this time shorted by private and institutional investors with about 7.89 trading days to cover. More on ProPhase Labs
Moving together with ProPhase Stock
| 0.76 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
Moving against ProPhase Stock
| 0.74 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.71 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
| 0.69 | VERV | Verve Therapeutics Downward Rally | PairCorr |
| 0.64 | VCNX | Vaccinex | PairCorr |
| 0.62 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.61 | VAXX | Vaxxinity Financial Report 14th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
ProPhase Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ProPhase Labs' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ProPhase Labs or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman and CEO | Ted Karkus | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering ProPhase Labs report their recommendations after researching ProPhase Labs' financial statements, talking to executives and customers, or listening in on ProPhase Labs' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ProPhase Labs. The ProPhase consensus assessment is calculated by taking the average forecast from all of the analysts covering ProPhase Labs. | |||||
ProPhase Labs' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ProPhase Labs' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ProPhase Labs' financial leverage. It provides some insight into what part of ProPhase Labs' total assets is financed by creditors.
| |||||
ProPhase Labs (PRPH) is traded on NASDAQ Exchange in USA. It is located in 711 Stewart Avenue, Garden City, NY, United States, 11530 and employs 113 people. ProPhase Labs is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 132.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ProPhase Labs's market, we take the total number of its shares issued and multiply it by ProPhase Labs's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ProPhase Labs conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 18.05 M outstanding shares of which 257.32 K shares are at this time shorted by private and institutional investors with about 7.89 trading days to cover.
ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Check ProPhase Labs Probability Of Bankruptcy
Ownership AllocationProPhase Labs has a total of 18.05 Million outstanding shares. ProPhase Labs has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check ProPhase Ownership Details
ProPhase Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of ProPhase Labs jumping above the current price in 90 days from now is about 10.82%. The ProPhase Labs probability density function shows the probability of ProPhase Labs stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days ProPhase Labs has a beta of -0.0932 indicating as returns on the benchmark increase, returns on holding ProPhase Labs are expected to decrease at a much lower rate. During a bear market, however, ProPhase Labs is likely to outperform the market. Additionally, proPhase Labs has an alpha of 0.454, implying that it can generate a 0.45 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of ProPhase Labs to move above the current price in 90 days from now is about 10.82 (This ProPhase Labs probability density function shows the probability of ProPhase Stock to fall within a particular range of prices over 90 days) .
ProPhase Stock Institutional Holders
Institutional Holdings refers to the ownership stake in ProPhase Labs that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ProPhase Labs' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProPhase Labs' value.| Instituion | Recorded On | Shares | |
| Chapin Davis Inc | 2023-12-31 | 40 K | |
| Bank Of America Corp | 2023-12-31 | 36.7 K | |
| Bridgeway Capital Management, Llc | 2023-12-31 | 22.6 K | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 17.3 K | |
| Commonwealth Equity Services Inc | 2023-12-31 | 16 K | |
| Tower Research Capital Llc | 2023-12-31 | 15 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 5.2 K | |
| Simplex Trading, Llc | 2023-12-31 | 3.3 K | |
| Citadel Advisors Llc | 2023-09-30 | 3.3 K | |
| Vanguard Group Inc | 2023-12-31 | 609.3 K | |
| Renaissance Technologies Corp | 2023-12-31 | 245.7 K |
ProPhase Labs Historical Income Statement
ProPhase Labs Income Statement is one of the three primary financial statements used for reporting ProPhase's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ProPhase Labs revenue and expense. ProPhase Labs Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, ProPhase Labs' Net Income Applicable To Common Shares is increasing as compared to previous years. The ProPhase Labs' current Non Operating Income Net Other is estimated to increase to about 74.9 K, while Selling General Administrative is projected to decrease to under 32.8 M. View More FundamentalsProPhase Stock Against Markets
Picking the right benchmark for ProPhase Labs stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ProPhase Labs stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ProPhase Labs is critical whether you are bullish or bearish towards ProPhase Labs at a given time. Please also check how ProPhase Labs' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in ProPhase Labs without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
ProPhase Labs Corporate Directors
ProPhase Labs corporate directors refer to members of a ProPhase Labs board of directors. The board of directors generally takes responsibility for the ProPhase Labs' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ProPhase Labs' board members must vote for the resolution. The ProPhase Labs board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Mark Burnett | Independent Director | Profile | |
| James McCubbin | Compliance Officer, Independent Director and Member of Audit Committee | Profile | |
| Mark Leventhal | Independent Director | Profile | |
| Louis Gleckel | Independent Director | Profile |
How to buy ProPhase Stock?
Before investing in ProPhase Labs, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ProPhase Labs. To buy ProPhase Labs stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of ProPhase Labs. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase ProPhase Labs stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located ProPhase Labs stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased ProPhase Labs stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ProPhase Labs, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ProPhase Stock please use our How to Invest in ProPhase Labs guide.
Already Invested in ProPhase Labs?
The danger of trading ProPhase Labs is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ProPhase Labs is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ProPhase Labs. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ProPhase Labs is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is ProPhase Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.98) | Revenue Per Share 2.579 | Quarterly Revenue Growth (0.84) | Return On Assets (0.15) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.